Holly Kordasiewicz Sells 362 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Holly Kordasiewicz sold 362 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $84.30, for a total transaction of $30,516.60. Following the sale, the executive vice president owned 22,096 shares of the company’s stock, valued at $1,862,692.80. The trade was a 1.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Stock Down 9.4%

Shares of Ionis Pharmaceuticals stock opened at $58.25 on Friday. The stock’s fifty day moving average is $75.78 and its 200-day moving average is $77.27. The firm has a market capitalization of $9.63 billion, a PE ratio of -28.14 and a beta of 0.36. Ionis Pharmaceuticals, Inc. has a 12-month low of $40.03 and a 12-month high of $86.74. The company has a quick ratio of 4.09, a current ratio of 4.10 and a debt-to-equity ratio of 2.75.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. The business had revenue of $246.09 million for the quarter, compared to the consensus estimate of $195.56 million. During the same period last year, the firm posted ($0.93) earnings per share. The firm’s quarterly revenue was up 86.4% compared to the same quarter last year. Equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.69 earnings per share for the current year.

Wall Street Analyst Weigh In

IONS has been the topic of several research reports. The Goldman Sachs Group upped their price objective on shares of Ionis Pharmaceuticals from $74.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, June 24th. Jefferies Financial Group lowered their target price on Ionis Pharmaceuticals from $113.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday. Raymond James Financial set a $87.00 price target on Ionis Pharmaceuticals in a report on Thursday. TD Cowen reaffirmed a “buy” rating and set a $108.00 price objective on shares of Ionis Pharmaceuticals in a research report on Monday, June 15th. Finally, Citigroup cut their price target on shares of Ionis Pharmaceuticals from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Friday. Eighteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $96.80.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Jain Global LLC lifted its stake in shares of Ionis Pharmaceuticals by 3,037.4% in the third quarter. Jain Global LLC now owns 225,739 shares of the company’s stock valued at $14,768,000 after buying an additional 218,544 shares during the period. DAVENPORT & Co LLC raised its stake in shares of Ionis Pharmaceuticals by 248.3% in the fourth quarter. DAVENPORT & Co LLC now owns 217,897 shares of the company’s stock valued at $17,238,000 after purchasing an additional 155,334 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Ionis Pharmaceuticals by 230.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 878,155 shares of the company’s stock worth $57,449,000 after purchasing an additional 612,362 shares during the period. SG Americas Securities LLC increased its holdings in Ionis Pharmaceuticals by 548.7% in the 4th quarter. SG Americas Securities LLC now owns 33,409 shares of the company’s stock valued at $2,643,000 after buying an additional 28,259 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Ionis Pharmaceuticals by 51.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 42,394 shares of the company’s stock valued at $3,354,000 after buying an additional 14,455 shares in the last quarter. 93.86% of the stock is owned by institutional investors.

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Negative Sentiment: Ionis and AstraZeneca disclosed that the Phase 3 CARDIO-TTRansform trial for eplontersen in ATTR-CM failed to hit its main efficacy goal, a major setback for a key partnered drug. Article Title
• Negative Sentiment: Reuters reported that the AstraZeneca-Ionis heart drug also missed its main goal of reducing cardiovascular deaths and recurrent heart problems, reinforcing investor concerns about the program. Article Title
• Negative Sentiment: Several insiders, including an executive vice president and a director, disclosed stock sales under pre-arranged 10b5-1 plans, adding to near-term caution.
• Negative Sentiment: Traders bought an unusually large number of put options, suggesting some market participants are positioning for further downside.
• Neutral Sentiment: Multiple analysts cut price targets on IONS, but most kept Buy/Overweight ratings, indicating valuation confidence even after the setback. Article Title
• Neutral Sentiment: HC Wainwright, Morgan Stanley, Canaccord Genuity, and Needham all lowered targets, with Needham trimming its target to $86 from $105 while maintaining a Buy rating. Article Title
• Neutral Sentiment: Ionis updated FY2026 revenue guidance to $875 million-$900 million, roughly in line with expectations, which does little to offset the clinical disappointment.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.